CRP to Serum Albumin Ratio in Type 2 DM é Diabetic Nephropathy

Sponsor

Assiut University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05681286

Collaborator

(none)

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

we aimed to compare C-reactive protein to serum albumin ( CAR) level of the T2DM patients with DN to those T2DM without DN

Condition or Disease	Intervention/Treatment	Phase
Type 2 DM /Diabetic Nephropathy

Detailed Description

Diabetic Nephropathy (DN) is a serious complication of Diabetes Mellitus associated with chronic and low-grade inflammatory burden affects around 30 % of diabetic patients It is the leading cause of end-stage renal failure worldwide and associated with cardio vascular diseases and increases mortality of diabetic patients It characterized by persistent albuminuria, raise in arterial blood pressure ,decrease in glomerular filtration rate (GFR) It associated with chronic low grade inflammation that's leads to increase glucose and activities inflammation Despite of the pathogenesis of DN is multifactorial, but local inflammatory process may result from both the metabolic and hemodynamic affection seen in DN sustained diabetes-related metabolic and haemodynamic perturbations can induce subclinical low-grade renal inflammation and drive kidney from repair response to damage process, eventually to renal fibrosis Chronic inflammatory processes not only play a principle role in the progression of micro vascular but also macro vascular complications in type 2 diabetes mellitus. An association between low -grade inflammation and type 2 diabetes has been described in recent studies .C- reactive protein to serum albumin ratio has attracted great attention recently , and used as biomarker in detection disease severity

, since type 2 Diabetes Mellitus and Diabetic Nephropathy(DN) is associated with low grade inflammation in recent studies. In this study investigator presume that C-reactive protein to serum albumin ratio ( CAR )levels could be associated with the progression of DN in patients with T2DM.

Study Design

Study Type:

Observational

Anticipated Enrollment :

70 participants

Observational Model:

Case-Only

Time Perspective:

Cross-Sectional

Official Title:

C-reactive Protein to Serum Albumin Ratio in Type 2diabetic Patients With Diabetic Nephropathy

Anticipated Study Start Date :

Aug 4, 2023

Anticipated Primary Completion Date :

Aug 4, 2024

Anticipated Study Completion Date :

Aug 4, 2025

Outcome Measures

Primary Outcome Measures

C-reactive protein to serum albumin ratio in type 2diabetic patients with diabetic nephropathy [Baseline]
comparison between CAR level è type 2 diabetic nephropathy patient and those without nephropathy

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Inclusion Criteria All type 2diabetic patients

Exclusion Criteria:

Type 1 diabetes is , patient t with liver cirrhosis, patient with active infection ,pregnant women,patients with cancer

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Assiut University

Investigators

Study Chair: Salah Argoon, Assuit u
Study Chair: Alshaimaa sayed, Assiut University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Shymaa shahhat Abodahab, Investigator, Assiut University

ClinicalTrials.gov Identifier:

NCT05681286

Other Study ID Numbers:

CAR level in type 2 DM

First Posted:

Jan 12, 2023

Last Update Posted:

Jan 31, 2023

Last Verified:

Dec 1, 2022

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Kidney Diseases

Diabetic Nephropathies

Study Results

No Results Posted as of Jan 31, 2023